Ipsen's Dysport Outperforms Botox in Spasticity Trial, Extending Duration of Effect

Event summary

  • Ipsen's Phase IV DIRECTION trial showed Dysport had a non-inferior safety profile to Botox in treating upper limb spasticity.
  • Patients treated with Dysport experienced a longer duration of effect (14.2 weeks vs. Botox's 13.8 weeks).
  • The trial involved 464 patients across 72 sites in the USA, France, and Canada.
  • Results were presented as a late-breaking session at the ISPRM congress on May 19, 2026.

The big picture

Ipsen's head-to-head trial against Botox addresses a long-standing evidence gap in spasticity treatment, potentially reshaping the competitive landscape. The focus on treatment duration aligns with patient needs, where over 80% experience breakthrough symptoms between injection cycles. This strategic move could strengthen Ipsen's position in the neuroscience therapeutic area, particularly if the data influences prescribing habits.

What we're watching

Market Positioning
Whether Ipsen can leverage these results to gain market share against Allergan's Botox in the spasticity treatment space.
Regulatory Impact
How regulatory bodies may interpret these findings and whether they influence treatment guidelines.
Commercial Strategy
The pace at which Ipsen can translate clinical advantages into commercial success, particularly in key markets like the USA and Europe.